Table 2.
Incidence of adverse events
| Total events/total number | Risk ratio (95% CI) | ||
|---|---|---|---|
| Tianqi capsule + LM | Placebo + LM | ||
| Gastrointestinal reactions | 7/240 | 9/240 | 0.78 (0.29, 2.05) |
| Rash | 1/210 | 0/210 | 3.00 (0.12, 73.22) |
| Weakness | 1/210 | 0/210 | 3.00 (0.12, 73.22) |
| Weight loss | 1/210 | 0/210 | 3.00 (0.12, 73.22) |
| Frequently urination | 1/210 | 0/210 | 3.00 (0.12, 73.22) |
| Tinnitus | 1/210 | 0/210 | 3.00 (0.12, 73.22) |
| Genital swelling | 0/210 | 1/210 | 0.33 (0.01, 8.14) |
| Elevated blood white blood cell | 1/210 | 0/210 | 3.00 (0.12, 73.22) |
| Decreased hemoglobin | 1/210 | 0/210 | 3.00 (0.12, 73.22) |
| Elevated urine white blood cell | 2/210 | 0/210 | 5.00 (0.24, 103.52) |
| Elevated urine protein | 0/210 | 1/210 | 0.33 (0.01, 8.14) |
| Total events | 16 | 11 | |
| Incidence of any adverse event | – | – |
Pooled rate ratio: 1.31 (0.69, 2.50) |